Suppr超能文献

可溶性尿激酶型纤溶酶原激活物受体(suPAR)对急诊科感染患者短期死亡率的预后价值

[Prognostic power of soluble urokinase plasminogen activator receptor (suPAR) for short-term mortality in patients seen in Emergency Departments due to infections].

作者信息

Rubio Díaz R, de Rafael González E, Martín Torres E, Valera Núñez E, López Martos A M, Melguizo Melguizo D, Picazo Perea M P, López García P J, Fuentes Bullejos P, Chafer Rudilla M, Carretero Gómez J F, Julián-Jiménez A

机构信息

Agustín Julián-Jiménez, Servicio de Urgencias-Coordinador de Docencia, Formación, Investigación y Calidad. Complejo Hospitalario Universitario de Toledo, Toledo, Spain.

出版信息

Rev Esp Quimioter. 2022 Feb;35(1):50-62. doi: 10.37201/req/108.2021. Epub 2021 Dec 3.

Abstract

OBJECTIVE

To analyse and compare 30-day mortality prognostic power of several biomarkers (C-reactive protein, procalcitonin, lactate and suPAR) in patients seen in emergency departments (ED) due to infections. Secondly, if these could improve the accuracy of systemic inflammatory response syndrome (SIRS) and quick Sepsis-related Organ Failure Assessment (qSOFA).

METHODS

A prospective, observational and analytical study was carried out on patients who were treated in an ED of one of the eight participating hospitals. An assessment was made of 32 independent variables that could influence mortality at 30 days. They covered epidemiological, comorbidity, functional, clinical and analytical factors.

RESULTS

The study included 347 consecutive patients, 54 (15.6%) of whom died within 30 days of visiting the ED. SUPAR has got the best biomarker area under the curve (AUC)-ROC to predict mortality at 30 days of 0.836 (95% CI: 0.765-0.907; P <.001) with a cut-off > 10 ng/mL who had a sensitivity of 70% and a specificity of 86%. The score qSOFA ≥ 2 had AUC-ROC of 0.707 (95% CI: 0.621-0.793; P < .001) with sensitivity of 53% and a specificity of 89%. The mixed model (suPAR > 10 ng/mL plus qSOFA ≥ 2) has improved the AUC-ROC to 0.853 [95% CI: 0.790-0.916; P < .001] with the best prognostic performance: sensitivity of 39% and a specificity of 97% with a negative predictive value of 90%.

CONCLUSIONS

suPAR showed better performance for 30-day mortality prognostic power from several biomarkers in the patients seen in ED due to infections. Score qSOFA has better performance that SRIS and the mixed model (qSOFA ≥ 2 plus suPAR > 10 ng/mL) increased the ability of qSOFA.

摘要

目的

分析并比较几种生物标志物(C反应蛋白、降钙素原、乳酸和可溶性尿激酶型纤溶酶原激活物受体[sPAR])对急诊科(ED)感染患者30天死亡率的预测能力。其次,研究这些生物标志物能否提高全身炎症反应综合征(SIRS)和快速脓毒症相关器官功能衰竭评估(qSOFA)的准确性。

方法

对参与研究的八家医院之一的急诊科收治的患者进行了一项前瞻性、观察性和分析性研究。评估了32个可能影响30天死亡率的独立变量。这些变量涵盖流行病学、合并症、功能、临床和分析因素。

结果

该研究纳入了347例连续患者,其中54例(15.6%)在就诊急诊科后30天内死亡。可溶性尿激酶型纤溶酶原激活物受体(sPAR)在预测30天死亡率方面具有最佳的曲线下面积(AUC)-ROC,为0.836(95%可信区间:0.765-0.907;P<.001),临界值>10 ng/mL时,敏感性为70%,特异性为86%。qSOFA评分≥2时,AUC-ROC为0.707(95%可信区间:0.621-0.793;P<.001),敏感性为53%,特异性为89%。混合模型(sPAR>10 ng/mL加qSOFA≥2)将AUC-ROC提高到0.853[95%可信区间:0.790-0.916;P<.001],具有最佳的预后性能:敏感性为39%,特异性为97%,阴性预测值为90%。

结论

在急诊科因感染就诊的患者中,可溶性尿激酶型纤溶酶原激活物受体(sPAR)在几种生物标志物中对30天死亡率的预测能力表现更佳。qSOFA评分比SIRS表现更好,且混合模型(qSOFA≥2加sPAR>10 ng/mL)提高了qSOFA的预测能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5e/8790637/da0b46c57ef3/revespquimioter-35-50-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验